NCT06440850View on ClinicalTrials.gov

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

November 22, 2026

Study Completion Date

November 22, 2026

Conditions
Thyroid Gland Follicular CarcinomaThyroid Gland Oncocytic CarcinomaThyroid Gland Papillary Carcinoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Cobimetinib

Given PO

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Diagnostic Imaging

Undergo I-123 diagnostic scan

PROCEDURE

I-131 Uptake Test

Undergo I-131 whole body scan

RADIATION

Iodine I-131

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET scan

BIOLOGICAL

Recombinant Thyrotropin Alfa

Given IM

PROCEDURE

Ultrasound Imaging

Undergo neck ultrasound

DRUG

Vemurafenib

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER